Literature DB >> 22967687

Under pressure: an ocular complication of oral corticosteroid therapy.

Lucy Anne Fitzgerald1, Jan Dudley, Carol Inward, Jane Tizard.   

Abstract

We describe the case of a patient with steroid sensitive nephrotic syndrome who is admitted with headaches, eye pain and reduced visual acuity. Despite thorough investigation no cause for the pain is identified. On a subsequent admission for recurrence of her symptoms her intraocular pressures are measured, which are markedly raised. Immediate medical treatment, as well as prompt weaning of her steroid therapy avoided the need for trabeculectomy surgery. We review this case and the literature surrounding this condition in children.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22967687      PMCID: PMC4544383          DOI: 10.1136/bcr-2012-006955

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  PSEUDOTUMOR CEREBRI ASSOCIATED WITH PROLONGED CORTICOSTEROID THERAPY. REPORTS OF FOUR CASES.

Authors:  A E WALKER; J J ADAMKIEWICZ
Journal:  JAMA       Date:  1964-06-01       Impact factor: 56.272

2.  STATISTICAL ATTRIBUTES OF THE STEROID HYPERTENSIVE RESPONSE IN THE CLINICALLY NORMAL EYE. I. THE DEMONSTRATION OF THREE LEVELS OF RESPONSE.

Authors:  M F ARMALY
Journal:  Invest Ophthalmol       Date:  1965-04

3.  Intraocular pressure and axial length in children.

Authors:  D H Youn; Y S Yu; I W Park
Journal:  Korean J Ophthalmol       Date:  1990-06

Review 4.  Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature.

Authors:  Relief Jones; Douglas J Rhee
Journal:  Curr Opin Ophthalmol       Date:  2006-04       Impact factor: 3.761

5.  Prospective, long-term evaluation of steroid-induced glaucoma.

Authors:  R Sihota; V L Konkal; T Dada; H C Agarwal; R Singh
Journal:  Eye (Lond)       Date:  2006-06-23       Impact factor: 3.775

6.  Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial.

Authors:  Dennis S C Lam; Dorothy S P Fan; Joan S K Ng; Christopher B O Yu; Chun Y Wong; Albert Y K Cheung
Journal:  Clin Exp Ophthalmol       Date:  2005-06       Impact factor: 4.207

7.  Steroid-induced glaucoma in children with acute lymphoblastic leukemia: a possible complication.

Authors:  Takehiro Yamashita; Yuichi Kodama; Minoru Tanaka; Keita Yamakiri; Yoshifumi Kawano; Taiji Sakamoto
Journal:  J Glaucoma       Date:  2010-03       Impact factor: 2.503

Review 8.  Ocular effects of topical and systemic steroids.

Authors:  L Renfro; J S Snow
Journal:  Dermatol Clin       Date:  1992-07       Impact factor: 3.478

9.  Ocular findings in Japanese children with nephrotic syndrome receiving prolonged corticosteroid therapy.

Authors:  Yoriko Hayasaka; Seiji Hayasaka; Hiroyoshi Matsukura
Journal:  Ophthalmologica       Date:  2006       Impact factor: 3.250

10.  Ocular hypertensive response to topical dexamethasone ointment in children.

Authors:  Yoon Jung Lee; Chan Yi Park; Kyung In Woo
Journal:  Korean J Ophthalmol       Date:  2006-09
View more
  3 in total

1.  Early and frequent development of ocular hypertension in children with nephrotic syndrome.

Authors:  Emi Kawaguchi; Kenji Ishikura; Riku Hamada; Yoshinobu Nagaoka; Yoshihiko Morikawa; Tomoyuki Sakai; Yuko Hamasaki; Hiroshi Hataya; Eiichiro Noda; Masaru Miura; Takashi Ando; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2014-05-24       Impact factor: 3.714

Review 2.  Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.

Authors:  Sherif A Gaballa; Uday B Kompella; Omar Elgarhy; Ali M Alqahtani; Barbara Pierscionek; Raid G Alany; Hamdy Abdelkader
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

3.  Republished: Severe acute ocular hypertension following pulsed methylprednisolone for juvenile idiopathic arthritis.

Authors:  Andrew Beverstock; Alison Kelly
Journal:  Drug Ther Bull       Date:  2019-08-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.